期刊名称 clinical and vaccine immunology
期刊缩写 CLIN VACCINE IMMUNOL
学科分类 医学
出版周期 月刊
审稿速度 1.5 个月 （平均）
投稿命中率 75 % （均值) 关键词:论文翻译润色,论文评估,SCI投稿,SCI期刊发表,医生出国进修
期刊主页 http://cvi.asm.org/
ISSN 号 (printed): 1556-6811 (electronic): 1556-679X
IF 趋势 2005 2006 2007 2008 2009 2010 2011 2012
0 0 1.995 2.237 2.373 2.471 2.546 2.598
被收录情况 1. Science Citation Index
2. Science Citation Index Expanded
3. Current Contents - Life Sciences
4. BIOSIS Previews
PubSci评语 主要关注免疫学及相关领域。需要交纳版面费、彩页费及补充材料费。一审一个月左右，修改后容易被接受，费用挺贵的。
期刊简介 CVI通过发表以下领域重要的临床相关研究增强了我们对健康和疾病状态下的免疫应答的认识：人类免疫疾病的新的动物模型、病毒免疫、免疫病理、临床实验室免疫。该刊尤其强调免疫和疫苗研究领域的重要发现，如疫苗的进展和评估、人和动物对疫苗 免疫应答、疫苗载体、佐剂和免疫调节剂、疫苗功效的定量分析以及临场实验。
投稿注意事项 特别提醒：需要交纳版面费，对于ASM会员，标准为前8页每页67美元，超出部分每页125美元。费ASM会员，标准为前8页135美元，超出部分每页250美元。彩页费需要额外交纳，ASM会员每张彩图45美元，费ASM会员每张彩图75美元。补充材料同样收费，ASM会员190美元，费ASM会员285美元，微综述和评论性文章不需交纳补充材料费。
一般注意事项：
2013 INSTRUCTIONS TO AUTHORS
SCOPE
Clinical and Vaccine Immunology (CVI) is devoted to the advancement
and dissemination of new knowledge about all aspects
of the immune response in health, in disease, and after
vaccination. CVI will welcome studies of (i) cellular and humoral
immunity in humans and animals; (ii) immunological
and immune-mediated disorders, including relevant new animal
models for immunologic diseases; (iii) microbial immunology;
(iv) viral immunopathogenesis; (v) assay development,
standardization, quality control, normal reference
values, and biostatistical issues; and (vi) immunoepidemiology.
In addition, the journal will publish articles on all aspects of
immunization and vaccine research, including (i) development
and evaluation of vaccines; (ii) mechanisms of vaccine
action; (iii) the immune response to vaccines in humans and
animals; (iv) studies of vaccine vectors, adjuvants, and immunomodulators;
(v) immunological correlates of vaccine efficacy;
and (vi) clinical trials, including phases 1 through 3.
ASM publishes a number of journals covering various aspects
of microbiology. Each journal has a prescribed scope that
must be considered in determining where to submit a manuscript.
Papers with a primary immunological or vaccine focus
are suitable for CVI; those with a primary focus on a microbe,
an infectious process, a mechanism of microbial pathogenesis
or host response, or animal models for microbial diseases are
best directed to one of the other ASM journals. The following
guidelines may be of assistance.
(i) Papers developing or evaluating animal models for human
immune disease and dysfunction are appropriate for CVI;
those dealing with development of animal models of microbial
pathogenesis should be sent to Infection and Immunity.
(ii) Papers with a primary focus on the immunology and
immunopathogenesis of human viral infections are appropriate
for CVI; those using an immunologic approach to basic
virology research are more appropriate for the Journal of Virology.
(iii) Papers that focus on the immunologic aspects of development
and evaluation of vaccines in humans and animals,
including clinical trials, may be sent to CVI; studies that focus
on establishing a proof of principle using nonviral microbial
antigens as immunogens or that describe the construction and
initial evaluation of novel bacterial vectors are suitable for Infection
and Immunity.
Commentaries, intended to raise issues and engender discussion,
will occasionally be solicited by the CVI editors.
Questions about these guidelines may be directed to the editor
in chief of the journal being considered.
If transfer to another ASM journal is recommended by an
editor, the corresponding author will be contacted.
Note that a manuscript rejected by one ASM journal on
scientific grounds or on the basis of its general suitability for
publication is considered rejected by all otherASMjournals.
EDITORIAL POLICY
Use of Microbiological Information
The Council Policy Committee (CPC) of the American Society
for Microbiology affirms the long-standing position of the Society
that microbiologists will work for the proper and beneficent
application of science and will call to the attention of the
public or the appropriate authorities misuses of microbiology
or of information derived from microbiology. ASM members
are obligated to discourage any use of microbiology contrary to
the welfare of humankind, including the use of microbes as
biological weapons. Bioterrorism violates the fundamental
principles expressed in the Code of Ethics of the Society and is
abhorrent to ASM and its members.
ASM recognizes that there are valid concerns regarding the
publication of information in scientific journals that could be
put to inappropriate use as described in the CPC resolution
mentioned above. Members of the ASM Publications Board
will evaluate the rare manuscript that might raise such issues
during the review process. However, as indicated elsewhere in
these Instructions, research articles must contain sufficient detail,
and material/information must be made available, to permit
the work to be repeated by others. Supply of materials
should be in accordance with laws and regulations governing
the shipment, transfer, possession, and use of biological materials
and must be for legitimate, bona fide research needs. Links
to, and information regarding, these laws and regulations can
be found at http://www.asm.org/ under the Public Policy tab.
We ask that authors pay particular attention to the NSAR Select
Agent/Toxin list on the CDC website http://www
.selectagents.gov/index.html and the NSABB criteria for identifying
dual use research of concern in the report “Proposed
Framework for the Oversight of Dual Use Life Sciences Research:
Strategies for Minimizing the Potential Misuse of Research
Information” on the Office of Biotechnology Activities
website http://oba.od.nih.gov/biosecurity/pdf/Framework%2
0for%20transmittal%200807_Sept07.pdf (p. 17–22).
Ethical Guidelines
ASM requirements for submitted manuscripts are consistent
with the Uniform Requirements for Manuscripts Submitted to
Biomedical Journals, as last updated by the International
Committee of Medical Journal Editors in April 2010 (http:
//www.icmje.org/).
Authors are expected to adhere to the highest ethical standards.
The following sections of these Instructions include detailed
information about ASM’s ethical standards. Failure to
comply with the policies described in these Instructions may
result in a letter of reprimand, a suspension of publishing privileges
in ASM journals, and/or notification of the authors’ in-
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
Instructions to Authors are updated throughout the year. The current version is
available at http://cvi.asm.org/site/misc/ifora.xhtml.
August 2013, Instructions to Authors, pages 1–20
August 2013, Instructions to Authors Clinical and Vaccine Immunology cvi.asm.org 1
stitutions. Authors employed by companies whose policies do
not permit them to comply with ASM policies may be sanctioned
as individuals and/or ASM may refuse to consider manuscripts
having authors from such companies. The ASM Publications
Board wishes to clarify the following in particular.
Plagiarism. Misappropriating another person’s intellectual
property constitutes plagiarism. This includes copying sentences
or paragraphs verbatim (or almost verbatim) from
someone else’s work, even if the original work is cited in the
references. The NIH ORI publication “Avoiding Plagiarism,
Self-Plagiarism, and Other Questionable Writing Practices: a
Guide to Ethical Writing” (http://ori.dhhs.gov/education
/products/plagiarism/) can help authors identify questionable
writing practices.
Plagiarism is not limited to the text; it can involve any part of
the manuscript, including figures and tables, in which material
is copied from another publication without permission and
attribution. An author may not reuse his or her own previously
published work without attribution; this is considered selfplagiarism.
Fabrication, manipulation, and falsification of data. As
a member of the Committee on Publication Ethics (COPE),
ASM encourages authors to consult COPE’s “Code of
Conduct and Best Practice Guidelines for Journal Editors”
(http: //publicationethics.org/files/Code_of_conduct_for_
journal_editors_0.pdf ). Fabrication, manipulation, and falsification
of data constitute misconduct. As defined by the U.S.
Department of Health and Human Services, fabrication is
“making up data or results and recording or reporting them,”
and falsification is “manipulating research materials, equipment,
or processes, or changing or omitting data or results
such that the research is not accurately represented in the research
record” (42 Code of Federal Regulations, §93.103). All
sources and methods used to obtain and analyze data, including
any electronic preprocessing, should be fully disclosed; detailed
explanations should be provided for any exclusions.
Primary publication. Manuscripts submitted to the journal
must represent reports of original research, and the original
data must be available for review by the editor if necessary.
By submission of a manuscript to the journal, the authors
guarantee that they have the authority to publish the work
and that the manuscript, or one with substantially the same
content, was not published previously, is not being considered
or published elsewhere, and was not rejected on scientific
grounds by another ASM journal. It is incumbent upon
the author to acknowledge any prior publication, including
his/her own articles, of the data contained in a manuscript
submitted to an ASM journal. A copy of the relevant work
should be submitted with the paper as supplemental material
for information only. Whether the material constitutes the
substance of a paper and therefore renders the manuscript unacceptable
for publication is an editorial decision.
In brief, a paper is not acceptable for submission to an ASM
journal if it, or its substance, has been made publicly available
in:
• A serial, periodical, or book
• A conference report or symposium proceedings
• A technical bulletin or company white paper
• A public website
• Any other retrievable source
The following do not preclude submission to, or publication
by, anASMjournal, as long as the posted data do not constitute
the substance of a submission:
• Posting of a method/protocol on a public website
• Posting of a limited amount of original data on a personal/
university/corporate website or websites of small
collaborative groups working on a problem
• Deposit of unpublished sequence data in a public database
• Preliminary disclosures of research findings as meeting
posters, webcast as meeting presentations, or published
in abstract form as adjuncts to a meeting, e.g.,
part of a program
• Posting of theses and dissertations on a personal/university-
hosted website
Availability of materials. By publishing in the journal, the
authors agree that, subject to requirements or limitations imposed
by laws or governmental regulations of the United
States, any DNAs, viruses, microbial strains, mutant animal
strains, cell lines, antibodies, and similar materials described in
the article are available from a national collection or will be
made available in a timely fashion, at reasonable cost, and in
limited quantities to members of the scientific community for
noncommercial purposes. The authors guarantee that they
have the authority to comply with this policy either directly or
by means of material transfer agreements through the owner.
Similarly, the authors agree to make available computer
programs, originating in the authors’ laboratory, that are the
only means of confirming the conclusions reported in the article
but that are not available commercially. The program(s)
and suitable documentation regarding its (their) use may be
provided by any of the following means: (i) as a program transmitted
via the Internet, (ii) as an Internet server-based tool, or
(iii) as a compiled or assembled form on a suitable medium
(e.g., magnetic or optical). It is expected that the material will
be provided in a timely fashion and at reasonable cost to members
of the scientific community for noncommercial purposes.
The authors guarantee that they have the authority to comply
with this policy either directly or by means of material transfer
agreements through the owner.
Permissions. The corresponding author is responsible for
obtaining permission from both the original author and the
original publisher (i.e., the copyright owner) to reproduce or
modify figures and tables and to reproduce text (in whole or in
part) from previous publications.
Permissions must be obtained no later than the modification
stage. The original signed permission(s) must be identified
as to the relevant item in the ASM manuscript (e.g., “permissions
for Fig. 1 in CVI00123-13”) and submitted to the
ASM production editor on request. In addition, a statement
indicating that the material is being reprinted with permission
must be included in the relevant figure legend or table footnote
of the manuscript. Reprinted text must be enclosed in quotation
marks, and the permission statement must be included as
running text or indicated parenthetically.
Instructions to Authors
2 August 2013, Instructions to Authors Clinical and Vaccine Immunology cvi.asm.org
It is expected that the authors will provide written assurance
that permission to cite unpublished data or personal communications
has been granted. For supplemental material intended
for posting by ASM (see “Supplemental Material”), if
the authors of the CVI manuscript are not also the owners of
the supplemental material, the corresponding author must
send to ASM signed permission from the copyright owner that
allows posting of the material, as a supplement to the article, by
ASM. The corresponding author is also responsible for incorporating
in the supplemental material any copyright notices
required by the owner.
Authorship. All authors of a manuscript must have agreed
to its submission and are responsible for its content (initial
submission and any subsequent versions), including appropriate
citations and acknowledgments, and must also have agreed
that the corresponding author has the authority to act on their
behalf in all matters pertaining to publication of the manuscript.
The corresponding author is responsible for obtaining
such agreements and for informing the coauthors of the manuscript’s
status throughout the submission, review, and publication
processes. Submitting a paper before all coauthors have
read and approved it is considered an ethical violation, as is
failure to credit someone who qualifies as a coauthor; however,
ASM does not itself investigate or attempt to resolve authorship
disputes.
An author is one who made a substantial contribution to the
overall design and execution of the experiments; therefore,
ASM considers all authors responsible for the entire paper.
Individuals who provided assistance, e.g., supplied strains or
reagents or critiqued the paper, need not be listed as authors
but may be recognized in the Acknowledgments section. ASM
does not permit “ghost authorship,” i.e., individuals who contribute
to the research, data analysis, and/or writing of an article
but who do not satisfy the requirements for authorship.
Examples of ghost authors include medical writers and employees
of pharmaceutical or device companies who have not
made a substantial contribution to the overall design and execution
of the experiments.
A study group, surveillance team, working group, consortium,
or the like (e.g., the Active Bacterial Core Surveillance
Team) may be listed as a coauthor in the byline if its contributing
members satisfy the requirements for authorship and
accountability as described in these Instructions. The names
(and institutional affiliations, if desired) of the contributing
members only may be given as a separate paragraph in the
Acknowledgments section.
If the contributing members of the group associated with the
work do not fulfill the criteria of substantial contribution to
and responsibility for the paper, the group may not be listed in
the author byline. Instead, it and the names of its contributing
members may be listed in the Acknowledgments section.
All authors must agree to the order in which their names are
listed in the byline. Statements regarding equal contributions
by two or more authors (e.g., C.J. and Y.S. contributed equally
to . . .) are permitted as footnotes and must be agreed to by all
of the authors. Other statements of attribution may be included
in the Acknowledgments section.
A change in authorship (order of listing, addition or deletion
of a name, or corresponding author designation) after
submission of the manuscript will be implemented only after
receipt of signed statements of agreement from all parties involved.
Disputes about authorship may delay or prevent review
and/or publication of the manuscript. Should the individuals
involved be unable to reach an accord, review and/or publication
of the manuscript can proceed only after the matter is
investigated and resolved by the authors’ institution(s) and an
official report of such and signed statements of agreement are
provided to ASM.
Conflict of interest. All authors are expected to disclose, in
the manuscript submittal letter, any commercial affiliations as
well as consultancies, stock or equity interests, and patentlicensing
arrangements that could be considered to pose a conflict
of interest regarding the submitted manuscript. (Inclusion
of a company name in the author address lines of the manuscript
does not constitute disclosure.) Details of the disclosure
to the editor will remain confidential. However, it is the responsibility
of authors to provide, in the Acknowledgments section,
a general statement disclosing financial or other relationships
that are relevant to the study. Examples of potentially
conflicting interests that should be disclosed include relationships
that might detract from an author’s objectivity in presentation of
study results and interests whose value would be enhanced by the
results presented. All funding sources for the project, institutional
and corporate, should be credited in the Acknowledgments section,
as described below. In addition, if a manuscript concerns a
commercial product, the manufacturer’s name must be indicated
in the Materials and Methods section or elsewhere in the text, as
appropriate, in an obvious manner.
Copyright
To maintain and protect the Society’s ownership and rights
and to continue to afford scientists the opportunity to publish
in high-quality journals, ASM requires the corresponding author
to sign a copyright transfer agreement on behalf of all the
authors. Unless this agreement is executed (without changes
and/or addenda), ASM will not publish the article.
In the copyright transfer agreement signed by an author,
ASM grants to that author (and coauthors) the right to republish
discrete portions of his/her (their) article in any other publication
(print, CD-ROM, and other electronic forms) of
which he/she is (they are) the author(s) or editor(s), on the
condition that appropriate credit is given to the original ASM
publication. This republication right also extends to posting
on a host computer to which there is access via the Internet.
Except as indicated below, significant portions of the article
may not be reprinted/posted without ASM’s prior written permission,
however, as this would constitute duplicate publication.
Authors may post their own published articles on their personal
or university-hosted (but not corporate, government, or
similar) websites without ASM’s prior written permission provided
that appropriate credit is given (i.e., the copyright lines
shown at the bottom of the first page).
Works authored solely by U.S. government employees are
not subject to copyright protection, so there is no copyright to
be transferred. However, the other provisions of the copyright
Instructions to Authors
August 2013, Instructions to Authors Clinical and Vaccine Immunology cvi.asm.org 3
transfer agreement, such as author representations of originality
and authority to enter into the agreement, apply to U.S.
government employee-authors as well as to other authors.
When funds from the Wellcome Trust or Research Councils
UK are used to pay an article open access fee, the article will be
published under the Creative Commons Attribution license
(CC-BY) in accordance with the funding organization’s open
access policies. Authors will be required to notify ASM and
complete the Author Warranty and Provisional License to
Publish at the time of submission.
Copyright for supplemental material (see “Supplemental
Material”) remains with the author, but a license permitting
the posting by ASM is included in the article copyright transfer
agreement. If the author of the article is not also the copyright
owner of the supplemental material, the corresponding author
must send to ASM signed permission from the owner that
allows posting of the material, as a supplement to the article, by
ASM. The corresponding author is also responsible for incorporating
into the supplemental material any copyright notices
required by the owner.
Funding Agency Repositories
The National Institutes of Health (NIH) requests that its
grantee and intramural authors provide copies of their accepted
manuscripts to PubMed Central (PMC) for posting in
the PMC Public Access Repository. However, CVI authors are
automatically in compliance with this policy and need take no
action themselves. For the past several years, ASM has deposited
in PubMed Central all publications from allASMjournals.
Further, ASM policy is that all primary research articles are
made available to everyone, free, 6 months after publication
through PubMed Central, HighWire, and international
PubMed Central-like repositories. By having initiated these
policies, ASM is in full compliance with NIH policy. For more
information, see http://publicaccess.nih.gov/. ASM also allows
CVI authors whose work was supported by funding agencies
that have public access requirements like those of the NIH
(e.g., the Wellcome Trust) to post their accepted manuscripts
in publicly accessible electronic repositories maintained by
those funding agencies. If a funding agency does not itself
maintain such a site, then ASM allows the author to fulfill that
requirement by depositing the manuscript (not the typeset article)
in an appropriate institutional or subject-based open repository
established by a government or noncommercial entity.
Since ASM makes the final, typeset articles from its primaryresearch
journals available free of charge on the ASM Journals
and PMC websites 6 months after final publication, ASM requests
that when submitting the accepted manuscript to PMC
or a similar public access site, the author specify that the posting
release date for the manuscript be no earlier than 6
months after publication of the typeset article by ASM and
that a link to the published manuscript on the journal website
be provided.
Clinical Trials
CVI requires the prospective registration (i.e., before the first
patient is enrolled) of a clinical trial in a public trials registry in
accordance with guidelines established by the International
Committee of Medical Journal Editors (ICMJE) (http://www.
icmje.org/publishing_10register.html). The ICMJE defines a
clinical trial as “any research project that prospectively assigns
human subjects to intervention or concurrent comparison or
control groups to study the cause-and-effect relationship between
a medical intervention and a health outcome.” Such
intervention may include drugs, surgical procedures, devices,
behavioral treatments, process-of-care changes, etc.
CVI does not require registration in a particular registry, but
the registry chosen must meet the following criteria, in agreement
with ICMJE recommendations. It must be a (i) accessible
to the public free of charge, (ii) open to all registrants, (iii)
managed by a not-for-profit organization, (iv) monitored by a
mechanism to ensure validity of registration data, and (v)
searchable electronically. A registration with missing fields or
uninformative terminology will be deemed inadequate.
The registry and the trial registration number must be included
at the end of the abstract. If a registration number is
available, the authors should state this number the first time a
trial acronym is used to refer to the trial being reported or to
other trials mentioned in the manuscript.
Use of Human Subjects or Animals in Research
The use of human subjects or animals for research purposes
关注Pubsci微信
微信公共账号：pubsci888
